In this Issue

Smart device usage has become an active part of in-store shopping. According to a recent poll of Accent-Health smart device owners, nearly 3-out-of-5 have used their phone or tablet to aid in product selection while shopping in-store. However, consumers are more likely to research their next TV on their mobile device than their prescription medication. According to AccentHealth VP market research, Natalie Hill, "When it comes to medical treatment, healthcare professionals remain the most trusted source for information.

An oft-cited 1998 report, recently repeated again by the surgeon general in the January/ February 2012 "Public Health Report," estimated that 125,000 U.S. citizens die each year due to complications related to adherence. Also worrisome is the statistic that one-third to one-half of all patients don't take medication as prescribed, and according to a 2011 study by Harvard, Brigham and Women's Hospital and CVS, up to one-quarter of these never fill prescriptions at all.

By now you probably have heard about "Walgreens University," the internal education center the company opened last month, complete with technology-enhanced classrooms, a mock drug store and video-conferencing capabilities for employee educational programs.

Competing in the new age of retail, where bricks, clicks and anything in between compete for a larger share of the omnichannel customer, will require new skill sets and a generally better-educated workforce. The winners will create a more personalized shopping experience that leverages the expertise in their stores.

It has been just over a year since Frank Scorpiniti took the helm at Canada's Rexall Pharma Plus. And, as the Canadian retail market continues to heat up, the company has officially taken the lid off a reinvention of its business, from its stores and its brand, to the products and services in its stores.

While the Food and Drug Administration released draft guidance on regulations for biosimilars in February 2012, the final regulations have yet to appear. But already, everyone from analysts to trade groups to drug makers is preparing for a time when knock-off versions of biotech drugs will become available.

A new report sheds light on some of the opportunities and challenges that exist in follow-on biologics, arguing that their opportunity to generate value depends on factors like the speed of development, clarity of regulation, ease of access and the roles of all stakeholders.

Like just about everybody else with a pulse these days, the coolest thing I own is my iPad. I know. How original — me and 53 million other people.

But there's a reason for that. The iPad reinvents the boring old way we used to do so many things, from how we shop to how we consume media. It is no surprise that iPad users spend twice as much as any other online customer. It's just so damn easy and cool, and well, fun.

Bob Miller has a knack for turnarounds. In 1999, he took over Rite Aid as chairman and CEO, helping to stabilize the drug store chain at a time when Rite Aid was on the brink of bankruptcy, and many analysts were projecting Rite Aid would fold.

Miller joined Rite Aid soon after building Fred Meyer into a supermarket powerhouse. Kroger acquired the Midwest chain in a $8 billion deal in 1999.

MIDDLETON, Tenn. — Fred's Super Dollar is piloting a new store concept called GetWell Drug and Dollar that features a heavy focus on pharmacy, OTC and value-oriented convenience basics. The 8,000-sq.-ft. locations, half the size of a typical Fred's, will field some 7,500 front-end SKUs, 30% of which will be comprised of health-and-wellness items.